Test Diagnoses and Monitors Thyroid Cancer After Surgery

A new laboratory test for the diagnosis and lifelong monitoring of medullary thyroid cancer patients after thyroid surgery, was launched globally (except in the US). Elevated concentrations of calcitonin in the blood are associated with the onset of this type of cancer.

The new test is an important component of medical assessment especially when the patient’s symptoms are not specific. When performed alongside further examinations, the calcitonin test supports final clinical clearance. Patients can be treated at an earlier stage with greater chances of success.

Roche (Basel, Switzerland) developed the Elecsys Calcitonin assay and launched it for patients with nonspecific tumors of the thyroid. “The development of new laboratory tests for cancer management reflects our key goal of diagnostic solutions that support healthcare professionals with clear, actionable information and can thus contribute to increasing patient survival,” said Roland Diggelmann, COO, Roche Diagnostics.

When performed alongside further examinations, the calcitonin test supports final clinical clearance. Patients can be treated at an earlier stage with greater chances of success. The test also expands Roche’s portfolio for improved thyroid management. Designed for use on Roche’s cobas modular analyzer platform, the immunoassay Elecsys Calcitonin offers healthcare professionals an integrated solution for accurate diagnosis and reliable patient monitoring, significantly improving medical decision-making and treatment planning.

Related Links:
Roche